Month: ខែ​កុម្ភៈ 2026

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regi......

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). GIC purchased 64,128,000 shares at an average price of approximately HK$12.18 per share, representing a total investment of roughly HK$781 million (approx. US$100 million). This transaction marks the official entry of one of the world's leading sovereign funds into Ascletis Pharma's shareholder base, drawing market attention to the renewed positioning of global long-term capital in China's innovative pharmaceutical sector.As one of the most representative sovereign funds globally, GIC's investment decisions highly emphasize certainty and the ability to navigate economic cycles. Its continuous increase in holdings in a single target usually means that its mid-to-long-term value judgment on the relevant assets has become clear. Unlike tactical tra......

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com...

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the categ......